The glycosphingolipid α-galactosylceramide (α-GalCer) is known to stimulate invariant natural killer T-cells (iNKTs) and is able to induce powerful antiviral immune responses. The present dose-escalating randomized placebo-controlled Phase I/II trial aimed to investigate antiviral activity and safety of α-GalCer as a novel class of treatment for chronic hepatitis B patients.
Methods
Patients were randomly assigned to 0.1 μg/kg (n=8), 1 μg/kg (n=6) or 10 μg/kg (n=6) α-GalCer or placebo (n=7) treatment.
Results
Almost all α-GalCer-treated patients showed a rapid and strong decrease in natural killer T-cell (NKT) numbers. Patients with high baseline NKT numbers showed immune activation, including natural killer cell activation, increased serum tumour necrosis factor-α and interleukin-6 levels, and development of fever. Three patients demonstrated a transient decrease in hepatitis B virus (HBV) DNA. Only one α-GalCer-treated patient had a sustained decrease in HBV DNA at the end of follow-up. Four patients discontinued therapy because of fever shortly after drug administration. No significant side effects were observed.
Conclusions
α-GalCer (0.1–10 μg/kg) used as mono-therapy for chronic hepatitis B infection resulted in a strong decrease of NKTs, but did not clearly affect HBV DNA and alanine aminotransferase levels. α-GalCer was poorly tolerated and is unlikely to be suitable as an alternative monotherapy to the current treatment regimen.
References
1.
KaneM.Global programme for control of hepatitis B infection.Vaccine1995; 13 Suppl 1: S47–S49.
LauG.K., PiratvisuthT., LuoK.X.Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.N Engl J Med2005; 352: 2682–2695.
4.
MarcellinP., LauG.K., BoninoF.Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.N Engl J Med2004; 351: 1206–1217.
5.
JanssenH.L., van ZonneveldM., SenturkH.Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.Lancet2005; 365: 123–129.
6.
JohnsonT.R., HongS., Van KaerL., KoezukaY., GrahamB.S.N.K.T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus.J Virol2002; 76: 4294–4303.
7.
ExleyM.A., BigleyN.J., ChengO.CD1d-reactive T-cell activation leads to amelioration of disease caused by diabetogenic encephalomyocarditis virus.J Leukoc Biol2001; 69: 713–718.
8.
van DommelenS.L., TabariasH.A., SmythM.J., Degli-EspostiM.A.Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells.J Virol2003; 77: 1877–1884.
9.
KawanoT., CuiJ., KoezukaY.CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.Science1997; 278: 1626–1629.
10.
ExleyM., GarciaJ., BalkS.P., PorcelliS.Requirements for CD1d recognition by human invariant Vα24+ CD4-CD8- T cells.J Exp Med1997; 186: 109–120.
11.
TaniguchiM., HaradaM., KojoS., NakayamaT., WakaoH.The regulatory role of Vα14 NKT cells in innate and acquired immune response.Annu Rev Immunol2003; 21: 483–513.
OhtekiT., MacDonaldH.R.Major histocompatibility complex class I related molecules control the development of CD4+8- and CD4-8- subsets of natural killer 1.1+ T cell receptor-α/β+ cells in the liver of mice.J Exp Med1994; 180: 699–704.
15.
KakimiK., GuidottiL.G., KoezukaY., ChisariF.V.Natural killer T cell activation inhibits hepatitis B virus replication in vivo.J Exp Med2000; 192: 921–930.
16.
KakimiK., LaneT.E., ChisariF.V., GuidottiL.G.Cutting edge: inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver.J Immunol2001; 167: 6701–6705.
17.
MehtaA.S., GuB., ConyersB.α-Galactosylceramide and novel synthetic glycolipids directly induce the innate host defense pathway and have direct activity against hepatitis B and C viruses.Antimicrob Agents Chemother2004; 48: 2085–2090.
18.
KawanoT., CuiJ., KoezukaY.Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells.Proc Natl Acad Sci U S A1998; 95: 5690–5693.
19.
GiacconeG., PuntC.J., AndoY.A Phase I study of the natural killer T-cell ligand α-galactosylceramide (KRN7000) in patients with solid tumors.Clin Cancer Res2002; 8: 3702–3709.
20.
NakagawaR., MotokiK., UenoH.Treatment of hepatic metastasis of the colon26 adenocarcinoma with an α-galactosylceramide, KRN7000.Cancer Res1998; 58: 1202–1207.
21.
KobayashiE., MotokiK., UchidaT., FukushimaH., KoezukaY.KRN7000, a novel immunomodulator, and its antitumor activities.Oncol Res1995; 7: 529–534.
22.
VeldtB.J., van der VlietH.J., von BlombergB.M.Randomized placebo controlled Phase I/II trial of α-galactosylceramide for the treatment of chronic hepatitis C.J Hepatol2007; 47: 356–365.
23.
PasS.D., FriesE., De ManR.A., OsterhausA.D., NiestersH.G.Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays.J Clin Microbiol2000; 38: 2897–2901.
24.
HeermannK.H., GerlichW.H., ChudyM., SchaeferS., ThomssenR.Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. Eurohep Pathobiology Group.J Clin Microbiol1999; 37: 68–73.
25.
van der MolenR.G., SprengersD., BiestaP.J., KustersJ.G., JanssenH.L.A.Favorable effect of adefovir on the number and functionality of myeloid dendritic cells of patients with chronic HBVHepatology2006; 44: 907–914.
26.
OsmanY., KawamuraT., NaitoT.Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide.Eur J Immunol2000; 30: 1919–1928.
27.
NakagawaR., NagafuneI., TazunokiY.Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by alpha-galactosylceramide in mice.J Immunol2001; 166: 6578–6584.
28.
van der VlietH.J., MollingJ.W., von BlombergB.M.Circulating Vα24+Vβ11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients.Clin Immunol2005; 114: 183–189.
29.
GadolaS.D., DulphyN., SalioM., CerundoloV.Vα24-JαQ-independent, CD1d-restricted recognition of α-galactosylceramide by human CD4+ and CD8αβ+ T lymphocytes.J Immunol2002; 168: 5514–5520.
30.
CarnaudC., LeeD., DonnarsO.Cutting edge: crosstalk between cells of the innate immune system: NKT cells rapidly activate NK cells.J Immunol1999; 163: 4647–4650.
TouraI., KawanoT., AkutsuY., NakayamaT., OchiaiT., TaniguchiM.Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide.J Immunol1999; 163: 2387–2391.
33.
IshikawaA., MotohashiS., IshikawaE.A Phase I study of α-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.Clin Cancer Res2005; 11: 1910–1917.
